Jolene Yin Ling Fu

Jolene Yin Ling Fu

Auto-generated profile, based on publicly available information

Jolene Yin Ling Fu

Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Journal of Virological Methods
Verified
Journal Article
Closed access
JFJolene Yin Ling Fu
Jolene Yin Ling Fu
YCYoong Min Chong
Yoong Min Chong
ISI-Ching Sam
I-Ching Sam
YCYoke Fun Chan
Yoke Fun Chan

25 March 2023 in Viruses
Verified
Journal Article
Open access
PDF file
JFJolene Yin Ling Fu
Jolene Yin Ling Fu
MPMuhammad Harith Pukhari
Muhammad Harith Pukhari
MBMaria Kahar Bador
Maria Kahar Bador
ISI-Ching Sam
I-Ching Sam
YCYoke Fun Chan
Yoke Fun Chan
Vaccine efficacy against SARS-CoV-2 could be compromised by the emergence of SARS-CoV-2 variants and it is important to study how it impacts the booster vaccination regime. We investigated the humoral and T cell responses longitudinally in vaccinated uninfected (n = 25) and post-COVID-19 individuals (n = 8), and those who had received a BNT162b2 booster following complete two-doses regimes of either BNT162b2 (homologous) (n = 14) or ChAdOx1-S (heterologous) (n = 15) vaccines, by means of a SARS-CoV-2 pseudovirus neutralization test and QuantiFERON SARS-CoV-2 assay. Vaccinated post-COVID-19 individuals showed higher neutralizing antibodies with longer durability against SARS-CoV-2 wild type (WT) and Omicron spikes, but demonstrated similar declining T cell responses compared to the uninfected vaccinated. Two doses of BNT162b2 induced higher neutralizing antibodies against WT and T cell responses than ChAdOx1-S for six months. The BNT162b2 booster confers a greater humoral response against WT, but a similar cross-neutralizing antibody against Omicron and T cell responses in the homologous booster group compared to the heterologous booster group. Breakthrough infection in the homologous booster group (n = 11) significantly increased the neutralizing antibody, but T cell responses remained low. Our data may impact government public health policy regarding the administration of mix-and-match vaccines, where both vaccination regimes can be employed should there be shortages of certain vaccines.

15 March 2024 in Journal of Global Health
Verified
Journal Article
Open access
JFJolene Yin Ling Fu
Jolene Yin Ling Fu
MPMuhammad Harith Pukhari
Muhammad Harith Pukhari
KCKristine Alvarado Dela Cruz
Kristine Alvarado Dela Cruz
ASAmin Soebandrio
Amin Soebandrio
LTLe Van Tan
Le Van Tan
PCPande Putu Ayu Rissa Cempaka
Pande Putu Ayu Rissa Cempaka
With a population exceeding 630 million (8% of the global population), the ten member states of the Association of Southeast Asian Nations (ASEAN) accounted for approximately 61 million (7.9%) of global COVID-19 cases and 808 166 (11.6%) of deaths, with case fatality rate (CFR) of 1.3% by the end of 2023 [1]. The actual figures are […]